POSTER SESSION I & WELCOME RECEPTION

Sunday, October 18, 2015: 6:30 PM - 8:30 PM
Grand Ballroom EH (Hyatt Regency St. Louis at the Arch)

PS1-1

BROADER ECONOMIC AND SOCIAL IMPACT OF IMMUNIZATION AGAINST VACCINE-PREVENTABLE DISEASES IN 73 GAVI COUNTRIES FROM 2001-2020
Samantha Clark, MHS1, Sachiko Ozawa, PhD, MHS1, Simrun Grewal, MHS2, Meghan Stack, MPH, MS1, Allison Portnoy, MSPH1, Peter Hansen3, Hope Johnson4, Michelle Li5 and Damian Walker, PhD6, (1)International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, (2)University of Washington, Seattle, WA, (3)Gavi, Washington, DC, (4)Gavi, Genève, Switzerland, (5)Gavi, Geneva, Switzerland, (6)BMGF, Seattle, WA
PS1-3

OVERTREATMENT AND COST-EFFECTIVENESS OF SEE-AND-TREAT APPROACH IN MANAGING CERVICAL SQUAMOUS INTRAEPITHELIAL LESIONS IN THE US SETTING
Kalatu R. Davies, Ph.D.1, Van T. Nghiem, M.S.P.H.1, J. Robert Beck, M.D.2, Michele Follen, MD, PhD3 and Scott B. Cantor, Ph.D.4, (1)The University of Texas MD Anderson Cancer Center, Department of Health Services Research, Houston, TX, (2)Fox Chase Cancer Center, Philadelphia, PA, (3)Department of Obstetrics & Gynecology, Brookdale University Hospital & Medical Center, Brooklyn, NY, (4)The University of Texas MD Anderson Cancer Center, Houston, TX
PS1-4

COST EFFECTIVENESS OF THERAPIES FOR CASTRATION RESISTANT METASTATIC PROSTATE CANCER
Niranjan Kathe, M.S., Corey Hayes, Pharm D MPH, Anand Shewale, M.S. and Bradley Martin, Pharm D PhD, University of Arkansas for Medical Sciences, Little Rock, AR
PS1-5

VALUE OF IMPLEMENTATION OF PHYSICAL EXERCISE FOR CANCER SURVIVORS
Janne Mewes, MSc1, Lotte Steuten, PhD2, Maarten J. IJzerman, PhD1 and Wim van Harten, Prof. Dr.3, (1)University of Twente, Enschede, Netherlands, (2)Fred Hutchinson Cancer Research Center, Seattle, WA, (3)University of Twente and the Netherlands Cancer Institute, Amsterdam, Netherlands
PS1-6

THE EFFECTIVENESS AND COST-EFFECTIVENESS OF IMPLEMENTING BICYCLE LANES IN THE PREVENTION OF OBESITY AND PERMANENT SEVERE INJURY
Yao Qiao*, MSc MPH1, Alyssa S Parpia*, MPH1 and Beate Sander2, (1)University of Toronto, Toronto, ON, Canada, (2)Public Health Ontario, Toronto, ON, Canada
PS1-7

CALIBRATING DYNAMIC COMPARTMENTAL MODELS OF HUMAN IMMUNODEFICIENCY VIRUS IN THE UNITED STATES
Yao-Hsuan Chen, PhD1, Emine Yaylali, PhD1, Katherine A. Hicks, MS2, Emily L. Tucker2, Paul G. Farnham, Ph.D.3 and Stephanie Sansom, PhD3, (1)CDC, Atlanta, GA, (2)RTI Health Solutions, Research Triangle Park, NC, (3)Centers for Disease Control and Prevention, Atlanta, GA
PS1-8

AT WHAT COST? EVALUATING RECENT TRENDS IN THE COSTS OF ORAL ANTICANCER DRUGS
Carrie Bennette, MPH, PhD, University of Washington, Seattle, WA, Catherine Richards, MPH, PhD, Hutchinson Center for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA and Scott Ramsey, MD, PhD, Hutchinson Center for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center / University of Washington, Seattle, WA
PS1-9

CHRONIC MYELOID LEUKEMIA TREATMENT: STARTING WITH A HIGHLY POTENT TYROSINE KINASE INHIBITOR AND EARLY SWITCHING TO IMATINIB?
Ursula Rochau, MD, MSc1, Durda Vukicevic, MD2, Stefan Schmidt, MD3, David Stenehjem, PharmD4, Diana Brixner, Prof., RPh, PhD5, Jerald Radich, Prof., MD6, Guenther Gastl, Prof., MD3 and Uwe Siebert, Prof., MD, MPH, MSc, ScD7, (1)UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and HTA, Department of Public Health and HTA/ ONCOTYROL - Center for Personalized Cancer Medicine, Area 4 HTA and Bioinformatics, Hall in Tyrol/ Innsbruck, Austria, (2)Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, Hall in Tirol, Austria, (3)Medical University Innsbruck, Innsbruck, Austria, (4)University of Utah, Department of Pharmacotherapy/ University of Utah Hospitals & Clinics, Huntsman Cancer Institute, Salt Lake City, UT, (5)UMIT-University for Health Sciences, Medical Informatics&Technology, Dept. Public Health&HTA/ ONCOTYROL - Center for Personalized Cancer Medicine, Area 4 HTA&Bioinformatics/ University of Utah, Dept. Pharmacotherapy&Program in Personalized Health Care, Hall in Tyrol/ Innsbruck/ Salt Lake City, Austria, (6)Fred Hutchinson Cancer Research Center, Seattle, WA, (7)UMIT, Dept. Public Health&HTA/ ONCOTYROL, Area 4 HTA&Bioinformatics/ Harvard T.H. Chan School Public Health, Center for Health Decision Science, Dept. Health Policy&Management/ Harvard Medical School, Institute for Technology Assessment&Dept. Radiology, Hall in Tyrol/ Innsbruck/ Boston, Austria
PS1-10

WHICH INFLUENZA VACCINE IS FAVORED IN 2 TO 8 YEAR OLDS? A COST-EFFECTIVENESS ANALYSIS
Kenneth J. Smith, MD, MS1, Jonathan M Raviotta, MPH1, Jay DePasse2, Shawn T Brown2, Eunha Shim3, Mary Patricia Nowalk1 and Richard K Zimmerman1, (1)University of Pittsburgh, Pittsburgh, PA, (2)Pittsburgh Supercomputing Center, Carnegie Mellon University, Pittsburgh, PA, (3)Soongsil University, Seoul, South Korea
PS1-12

A COST-EFFECTIVENESS STUDY OF HOME-BASED STROKE REHABILITATION
Laura Allen, M.Sc.1, Ava John-Baptiste, PhD2, Marina Richardson, M.Sc.3, Matthew Meyer, Ph.D1, Mark Speechley, Ph.D1, David Ure4, Deb Willems5 and Robert Teasell, MD6, (1)Western University, Department of Epidemiology and Biostatistics, London, ON, Canada, (2)Western University, London, ON, Canada, (3)Lawson Health Research Institute, Aging, Rehabilitation and Geriatric Care, London, ON, Canada, (4)St. Joseph's Health Care, London, London, ON, Canada, (5)Southwestern Ontario Stroke Network, London, ON, Canada, (6)Schulic School of Medicine and Dentistry, London, ON, Canada
PS1-13

TRAINING PRIMARY CARE PHYSICIANS IN SHARED DECISION MAKING FOR COLORECTAL CANCER SCREENING. INSIGHTS FROM A STATEWIDE COLORECTAL CANCER SCREENING PROGRAM IN SWITZERLAND
Kevin Selby, MD, Jean-Luc Bulliard, PD, PhD, Cristina Nichita, MD, David Gachoud, MD, MEd, Gian Dorta, MD, Cyril Ducros, MD, Jacques Cornuz, MD, MPH and Reto Auer, MD, MAS, University of Lausanne, Lausanne, Switzerland
PS1-14

PARENTAL DECISION MAKING INVOLVEMENT AND DECISIONAL CONFLICT: A DESCRIPTIVE STUDY
Laura Boland, MSc, PhD(c), University of Ottawa, Institute of Population Health, Ottawa, ON, Canada, Jennifer Kryworuchko, PhD, RN, CNCC(C), University of Saskatchewan College of Nursing, Saskatoon, SK, Canada, Anton Saarimaki, MCS, Ottawa Hospital Research Institute, Ottawa, ON, Canada and Margaret L. Lawson, MD, MSc, FRCP, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada
PS1-15

PREFERENCE FOR DECISION MAKING ROLE IN PROSTATE CANCER SURVIVORS IS ASSOCIATED WITH ILLNESS PERCEPTIONS AND SATISFACTION WITH INFORMATION PROVISION: RESULTS FROM THE PROFILES-REGISTRY
Maarten Cuypers, MSc.1, Romy R.E.D. Lamers, MD2, Olga Husson, PhD1, Paul J.M. Kil, MD, PhD2, Marieke de Vries, PhD1 and Lonneke V. van de Poll-Franse, PhD1, (1)Tilburg University, Tilburg, Netherlands, (2)St. Elisabeth Hospital, Tilburg, Netherlands
PS1-16

TREATMENT DECISION MAKING IN LOW-RISK PROSTATE CANCER: RECRUITMENT AND DATA COLLECTION FEASIBILITY
Shellie Ellis, MA, PhD1, Brantley Thrasher, MD1, Emily Jones2 and Kim Kimminau, PhD3, (1)University of Kansas School of Medicine, Kansas City, KS, (2)University of Kansas, Kansas City, KS, (3)Univeristy of Kansas School of Medicine, Kansas City, KS
PS1-17

PHYSICIANS' FIRST IMPRESSIONS IN THE DIAGNOSIS OF EARLY CANCERS
Olga Kostopoulou, PhD1, Miroslav Sirota2, Thomas Round2, Shyamalee Samaranayaka2 and Brendan C. Delaney, MD1, (1)King's College London, London, United Kingdom, (2)Department of Primary Care and Public Health Sciences, London, United Kingdom
PS1-18

PROSTATE CANCER PATIENTS' PREFERENCES FOR INFORMATION AND DECISION SUPPORT: WHERE, WHEN, AND HOW?
Deb Feldman-Stewart, PhD1, Christine Tong, MSc1, Michael Brundage, MD, MSc1, John Robinson, PhD2, Jackie Bender, PhD3 and Hannah Carolan, MD4, (1)Queen's University, Kingston, ON, Canada, (2)Tom Baker Cancer Centre, Calgary, AB, Canada, (3)University Health Network, Toronto, ON, Canada, (4)British Columbia Cancer Agency, Vancouver, BC, Canada
PS1-19

IMPLEMENTATION OF DECISION AIDS FOR IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS: LESSONS LEARNED AND PATIENT PERSPECTIVES
Jacqueline Jones, PhD, RN1, Carolyn Nowels, MSPH2, B. Karen Mellis3, Amy Jenkins, MS3, Heather Nuanes4, Paul Varosy, MD5, Richard Thomson, MD6, Glyn Elwyn, MD, MSc, PhD7, David J. Magid, MD, MPH8, Angela Brega, PhD3, Travis Vermilye, MFA9, Fred Masoudi, MD, MSPH10 and Daniel Matlock, MD, MPH11, (1)University of Colorado College of Nursing, Aurora, CO, (2)The University of Colorado Denver, Aurora, CO, (3)University of Colorado, Denver, Aurora, CO, (4)Kaiser Permanente- Institute for Health Research, Denver, CO, (5)Denver Veterans Affairs Medical Center, Denver, CO, (6)Newcastle University, NE1 7RU, United Kingdom, (7)The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, (8)The Kaiser Institute for Health Research, Denver, CO, (9)University of Colorado, Denver, Denver, CO, (10)University of Colorado School of Medicine, Aurora, CO, (11)University of Colorado School of Medicine, Division of General Internal Medicine, Aurora, CO
PS1-20

CONSIDERING PATIENT VALUES AND PREFERENCES ENHANCES PATIENT INVOLVEMENT IN RECTAL CANCER TREATMENT DECISION MAKING
Marleen Kunneman, MA1, Arwen H. Pieterse, PhD1, Corrie Marijnen, MD PhD2 and Anne M. Stiggelbout, PhD3, (1)Leiden University Medical Center, Leiden, Netherlands, (2)Leiden University Medical Center, Dept of Radiotherapy, Leiden, Netherlands, (3)LUMC, Leiden, Netherlands
PS1-21

DECISION CONSULTATIONS ABOUT (NEO-)ADJUVANT CANCER TREATMENT: PATIENT AND ONCOLOGIST QUESTIONS AS A VEHICLE TO PROMOTE SHARED DECISION MAKING
Anne M. Stiggelbout, PhD1, Marleen Kunneman, MA2, Ellen G. Engelhardt, MSc.2, Johanneke Portielje, MD, PhD3, Corrie Marijnen, MD PhD4, Ellen MA Smets, PhD5 and Arwen H. Pieterse, PhD2, (1)LUMC, Leiden, Netherlands, (2)Leiden University Medical Center, Leiden, Netherlands, (3)Haga Ziekenuis, The Hague, Netherlands, (4)Leiden University Medical Center, Dept of Radiotherapy, Leiden, Netherlands, (5)Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
PS1-22

ATTITUDES TOWARD SCREENING AND LUNG CANCER RISK PERCEPTIONS AMONG VETERANS INVITED TO AND SCHEDULING LUNG CANCER SCREENING
Sarah Lillie, PhD, MPH1, Steven Fu, MD1, Angela Fabbrini, MPH2, Kathryn Rice, MD2, Ann Bangerter, BS1, Barbara Clothier, MA, MS1, Tam Do, BA1, Elizabeth Doro1, M. Anas Moughrabieh, MD3, David Nelson, PhD1 and Melissa Partin, PhD1, (1)Minneapolis VAHCS Center for Chronic Disease Outcomes Research, Minneapolis, MN, (2)Minneapolis VAHCS Pulmonary Section, Minneapolis, MN, (3)University of Minnesota, Minneapolis, MN
PS1-23

THE ASSOCIATION BETWEEN INVOLVEMENT OF SIGNIFICANT OTHERS IN BREAST CANCER TREATMENT DECISIONS AND THEIR LONG-TERM DISTRESS
Kathryn A. Martinez, PhD, MPH, Ann Arbor, MI, Nancy Janz, PhD, University of Michigan, School of Public Health, Ann Arbot, MI and Sarah T. Hawley, PhD, MPH, University of Michigan, Ann Arbor VA Health System, Ann Arbor, MI
PS1-24

QUITADVISOROB: FEASIBILITY AND ACCEPTABILITY OF AN EVIDENCE-BASED DECISION TOOL FOR TOBACCO CESSATION IN THE OBSTETRIC/GYNECOLOGIC SETTING
Michael Mejia, B.A.1, Meghan Johnson, B.A.2, Hannah Knudsen, Ph.D.1, William Stoops, Ph.D.1, Christina Studts, Ph.D.2, Wendy Hansen, M.D.1, George Reynolds, B.A.3 and Jamie L. Studts, PhD1, (1)University of Kentucky College of Medicine, Lexington, KY, (2)University of Kentucky College of Public Health, Lexington, KY, (3)Health Decision Technologies, LLC, Oakland, CA
PS1-25

EXPERT OPINION OF TREATMENT DECISION MAKING IN PATIENTS WITH EARLY STAGE NON-SMALL CELL LUNG CANCER
Sahar Mokhles, BSc1, Alex Maat, MD1, Joachim Aerts, MD PhD1, Joost Nuyttens, MD PhD2, Ad Bogers, MD PhD1 and Johanna Takkenberg, MD PhD3, (1)Erasmus University Medical Center, Rotterdam, Netherlands, (2)Erasmus MC Cancer Institute, Rotterdam, Netherlands, (3)Erasmus MC, Rotterdam, Netherlands
PS1-26

PATIENT AND HEALTHCARE PROVIDER INVOLVEMENT IN THE DEVELOPMENT OF A PATIENT DECISION AID FOR THOSE WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA
Thomas LeBlanc, MD, MA1, David Rizzieri, MD2, Robert Wolf, PharmD3, Ellen Neylon, MSN, FNP-BC, RN, OCN4, Valerie Caroselli, PharmD5, Katie Deering, PharmD5 and Brad Schenkel, MS6, (1)Duke University School of Medicine, Durham, NC, (2)Duke University Medical Center, Durham, NC, (3)Mayo Clinic, Rochester, MN, (4)Center for Lymphoid Malignancies at Columbia University Medical Center, New York, NY, (5)EPI-Q, Inc., Oak Brook, IL, (6)Janssen Scientific Affairs, LLC, Horsham, PA
PS1-27

COMPARING THE CONCERNS AND BIASES OF VACCINATING AND NON-VACCINATING PARENTS: A QUESTION OF DEGREE, NOT CHARACTER
Aaron M. Scherer, PhD1, Megan Knaus, MPH1, Brian J. Zikmund-Fisher, PhD1 and Angela Fagerlin, PhD2, (1)University of Michigan, Ann Arbor, MI, (2)VA Ann Arbor Healthcare System & University of Michigan, Ann Arbor, MI
PS1-28

RISK OF ARM LYMPHEDEMA WITH TAXANE AND ANTHRACYCLINE USE AMONG PATIENTS WITH BREAST CANCER
Anand Shewale, MS1, Amanda Stolarz, PharmD1, Jacob Painter, PharmD, PhD, MBA1, Nancy Rusch, PhD1, Anuj Shah, B. Pharm2 and Lori Fischbach, PhD, MPH1, (1)University of Arkansas for Medical Sciences, LITTLE ROCK, AR, (2)University of Arkansas for Medical Sciences, Little Rock, AR
PS1-29

CONSENT TO TREAT FORMS FALL SHORT OF PROVIDING INFORMATION TO GUIDE DECISION MAKING
Christine Manta, BA1, Jacqueline Ortiz, MPhil2, Benjamin Moulton, JD, MPH3, Kimberly Williams, MPH4 and Seema S. Sonnad, PhD1, (1)Christiana Care Health System Value Institute, Newark, DE, (2)Christiana Care Health System, Newark, DE, (3)Informed Medical Decisions Foundation, Boston, MA, (4)Value Institute, Christiana Care Health System, Newark, DE
PS1-30

MALE AND FEMALE COLLEGE STUDENTS HAVE A POOR UNDERSTANDING OF HPV AND HPV VACCINES
A. Scott LaJoie, PhD, MSPH, Jelani C. Kerr, PhD, MSPH, Edna Ross, PhD, Richard D. Clover, MD and Diane M. Harper, MD, MPH, MS, University of Louisville, Louisville, KY
PS1-31

CAREGIVERS' AND PATIENTS' RESPONSES TO THE IMPLEMENTATION OF A DECISION AID FOR PROSTATE CANCER TREATMENT
Julia van Tol-Geerdink, PhD1, Inge van Oort, MD PhD1, Rik Somford, MD PhD2, Carl Wijburg, MD PhD3, Arno Geboers, MD PhD4 and Peep Stalmeier, PhD1, (1)Radboud UMC, Nijmegen, Netherlands, (2)Canisius Wilhelmina Hospital, Nijmegen, Netherlands, (3)Rijnstate Hospital, Arnhem, Netherlands, (4)Slingeland Hospital, Doetinchem, Netherlands
PS1-33

NOT MY CHILD: DOES OPTIMISM BIAS INFLUENCE PARENT PREDICTIONS OF CHILDHOOD-OBESITY RELATED DISEASE RISKS?
Davene R. Wright, PhD1, Paula Lozano, MD, MPH2, Elizabeth Dawson-Hahn, MD1, Dimitri Christakis, MD, MPH1, Wren Haaland, MPH1 and Anirban Basu, PhD3, (1)Seattle Children's Research Institute, Seattle, WA, (2)Group Health Research Institute, Seattle, WA, (3)Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Seattle, WA
PS1-34

HOW GOOD A JOB ARE WE RHEUMATOLOGISTS DOING IN SCREENING FOR HEPATITIS B & C BEFORE INITIATING IMMUNO-SUPPRESIVE/S IN SLE ?
Meenakshi Jolly and Chandrahasa Annem, RUSH UNIVERSITY, CHICAGO, IL
PS1-35

A NOVEL TOOL TO EVALUATE THE ACCURACY OF PREDICTING SURVIVAL IN CYSTIC FIBROSIS
Aasthaa Bansal, PhD1, Patrick Heagerty, PhD1, Nicole Hamblett, PhD2 and Christopher Goss, MD, MS, FCCP1, (1)University of Washington, Seattle, WA, (2)Seattle Children's Research Institute, Seattle, WA
PS1-36

PORTFOLIO MANAGEMENT TO INFORM CANCER CLINICAL TRIALS RESEARCH INVESTMENT DECISIONS IN THE US: A PROOF OF CONCEPT EVALUATION
Carrie Bennette, MPH, PhD1, Anirban Basu, PhD2, Josh Carlson, MPH, PhD1, Joshua A. Roth, PhD, MHA3, Scott Ramsey, MD, PhD4 and David Veenstra, PharmD, PhD1, (1)University of Washington, Seattle, WA, (2)Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Seattle, WA, (3)Fred Hutchinson Cancer Research Center, Seattle, WA, (4)Hutchinson Center for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center / University of Washington, Seattle, WA
PS1-37

PROJECTIONS OF RACIAL AND ETHNIC DISPARITIES IN HUMAN PAPILLOMAVIRUS (HPV)-RELATED CANCER BURDEN FOLLOWING INTRODUCTION OF HPV VACCINATION IN THE UNITED STATES
Emily A Burger, PhD, Harvard T. H. Chan School of Public Health, Boston, MA, Kyueun Lee, MSc, Harvard Center for Health Decision Science, Boston, MA and Jane J. Kim, PhD, Harvard T.H. Chan School of Public Health, Boston, MA
PS1-38

VARIATION IN TREATMENT DECISIONS IN TRAUMATIC BRAIN INJURY: PREDICTORS AND ASSOCIATIONS WITH OUTCOME
Maryse C. Cnossen, MSc.1, Suzanne Polinder, PhD.1, Teuntje Andriessen, MSc.2, Joukje Naalt, van der, PhD.3, Iain Haitsma, PhD.1, Janneke Horn, PhD.4, Gaby Franschman, PhD.5, Peter Vos, PhD.2, Ewout W. Steyerberg, PhD6 and Hester F. Lingsma, PhD.7, (1)Erasmus University Medical Center, Rotterdam, Netherlands, (2)Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, (3)University Medical Center Groningen, Groningen, Netherlands, (4)Academic Medical Center Amsterdam, Amsterdam, Netherlands, (5)VU University Medical Center, Amsterdam, Netherlands, (6)Erasmus MC, University Medical Center, Department of Public Health, Rotterdam, Netherlands, (7)Erasmus MC, Rotterdam, Netherlands
PS1-39

ECONOMIC TRENDS FROM 2004 – 2011 FOR CLOSTRIDIUM DIFFICILE INFECTION FOR INTENSIVE CARE AND OTHER INPATIENTS: A RETROSPECTIVE, COHORT STUDY
Matthew Hutcherson, BS1, Nicole Zimmerman, MS2, Chiedozie Udeh, MD3, J. Steven Hata, MD4, Joe Zein, MD5, Abhishek Deshpande, MD6, Simon Lam, PharmD, RPh7, Jarrod E. Dalton, PhD8 and Belinda Udeh, PhD, MPH1, (1)Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, (2)Departments of Outcomes Research and Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, (3)Critical Care Center and Department of Cardiothoracic Anesthesiology, Cleveland Clinic, Cleveland, OH, (4)Critical Care Center and Departments of General Anesthesiology and Cardiothoracic Anesthesiology, Cleveland Clinic, Cleveland, OH, (5)Departments of Pulmonary Medicine and Critical Care Medicine, Cleveland Clinic, Cleveland, OH, (6)Center for Value Based Care Research, Medicine Institute, Cleveland Clinic, Cleveland, OH, (7)Department of Pharmacy, Cleveland Clinic, Cleveland, OH, (8)Cleveland Clinic, Cleveland, OH
PS1-40

PARTNER SERVICES PROGRAMS FOR CHLAMYDIAL INFECTION: A COMPARISON BETWEEN PARTNER NOTIFICATION AND EXPEDITED PARTNER THERAPY
Szu-Yu Zoe Kao, MA1, Karen M. Kuntz, ScD2 and Eva Enns, MS, PhD2, (1)University of Minnesota School of Public Health, Minneapolis, MN, (2)University of Minnesota, Minneapolis, MN
PS1-41

SOCIAL MEDIA AS A KEY TOOL TO RECRUIT RARE DISEASE PATIENTS FOR CLINICAL RESEARCHERS
Chang Ho Lee, BSc1, Karen E Bremner, BSc2, Paul Grootendorst, PhD1, Jolie Ringash, MD, MSc3, Murray D Krahn, MD, MSc, FRCPC4 and Nicholas Mitsakakis, MSc PhD4, (1)University of Toronto, Toronto, ON, Canada, (2)University Health Network, Toronto, ON, Canada, (3)University of Toronto and the Princess Margaret Cancer Centre (PMCC), Toronto, ON, Canada, (4)Toronto Health Economics and Technology Assessment (THETA) Collaborative, University of Toronto, Toronto, ON, Canada
PS1-42

PRIORITIZING SUPPORT FOR INTERVENTION STUDIES THAT AIM TO IMPROVE RETENTION IN ANTIRETROVIRAL THERAPY PROGRAMS IN EAST AFRICA
Jennifer Uyei, PhD MPH, Lingfeng Li, PhD and R. Scott Braithwaite, MD, MSc, FACP, New York University School of Medicine, New York, NY
PS1-43

IMPACT OF TELEHOMECARE PROGRAM ON PATIENTS' QUALITY OF LIFE AND DISEASE-MANAGEMENT SKILLS
Valeria E. Rac, MD, PhD1, Yeva Sahakyan, MD, MPH1, Nida Shahid, HBSc., CCRP1, Iris Fan, BA2 and Murray Krahn, MD, Msc, FRCPC2, (1)Toronto Health Economics and Technology Assessment (THETA) Collaborative, University of Toronto, Toronto, ON, Canada, (2)Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada
PS1-44

NEW MODEL OF HEALTHCARE DELIVERY-TELEHOMECARE PROGRAM FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND HEART FAILURE (HF) PATIENTS IN ONTARIO, CANADA
Valeria E. Rac, MD, PhD1, Yeva Sahakyan, MD, MPH1, Nida Shahid, HBSc., CCRP1, Aleksandra Stanimirovic, MSc, PhD (candidate)1, Iris Fan, BA2, Welson Ryan1 and Murray Krahn, MD, Msc, FRCPC2, (1)Toronto Health Economics and Technology Assessment (THETA) Collaborative, University of Toronto, Toronto, ON, Canada, (2)Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada
PS1-45

PRIMARY CARE PROVIDER PARTICIPATION IN BREAST CANCER TREATMENT DECISIONS: RESULTS FROM THE ICANCARE STUDY
Lauren Wallner, PhD, MPH1, Paul Abrahamse1, Steven Katz, MD, MPH2 and Sarah T. Hawley, PhD, MPH2, (1)University of Michigan, Ann Arbor, MI, (2)University of Michigan, Ann Arbor VA Health System, Ann Arbor, MI
PS1-46

MODELING THE RISK OF COLORECTAL LESIONS BASED ON A MIXED CHINESE COHORT
Xiaolei Xie, Ph.D.1, Jie Xing2, Wenying Zhou1, Nan Kong, Ph.D.3 and Shutian Zhang, M.D.2, (1)Tsinghua University, Beijing, China, (2)National Clinical Research Center for Digestive Diseases of China, Beijing, China, (3)Purdue University, West Lafayette, IN
PS1-47

HEALTH-RELATED QUALITY OF LIFE, COMORBIDITIES AND MORTALITY IN NONTUBERCULOUS MYCOBACTERIAL INFECTIONS: A SYSTEMATIC REVIEW
Man Wah Yeung1, Edwin Khoo, MPH1, Sarah Brode2, Frances Jamieson1, Hiroyuki Kamiya3, Jeffrey Kwong1, Liane Macdonald1, Theodore Marras4, Kozo Morimoto5 and Beate Sander1, (1)Public Health Ontario, Toronto, ON, Canada, (2)Department of Medicine, University of Toronto, Toronto, ON, Canada, (3)Japanese Red Cross Medical Center, Tokyo, Japan, (4)Toronto Western Hospital, Toronto, ON, Canada, (5)Fukujuji Hospital, Tokyo, Japan
PS1-48

RISK FACTORS FOR COST-RELATED MEDICATION NON-ADHERENCE AMONG OLDER PATIENTS WITH CANCER
James Zhang, PhD and David Meltzer, MD/PhD, University of Chicago, Chicago, IL
PS1-49

VALIDATION OF A DOMAIN ASSESSING THE ENGAGEMENT OF GENERAL PRACTITIONERS TOWARD VACCINATION USING THE RASCH MODEL
Fatoumata Fofana, MSc1, Khadra Benmedjahed1, Pascale Arnould, MD2, Guillaume Coindard, MD2, François Denis, MD3, Didier Duhot, MD2, Jean-Luc Gallais, MD2, Luc Martinez, MD2, François Raineri, MD2, Antoine Regnault, PhD1, Didier Seyler, MD2, Béatrice Tugaut1 and Benoit Arnould, PhD1, (1)Mapi, Health Economics and Outcomes Research and Strategic Market Access, Lyon, France, (2)French Society of General Medicine (SFMG), Issy les Moulineaux, France, (3)University Hospital, Bacteriology and Virologie department, Limoges, France
PS1-50

A DISCRETE CHOICE EXPERIMENT (DCE) TO ELICIT PREFERENCES FOR ATTRIBUTES OF A BEDSIDE PHARMACOGENETIC TEST – PILOT TEST RESULTS
Basil G. Bereza, CFA MSc PhD (Candidate), University of Toronto, Toronto, ON, Canada, Doug Coyle, MA, MSc, PhD, University of Ottawa, School of Epidemiology, Public Health and Preventive Medicine, Ottawa, ON, Canada and Manny Papadimitropoulos, PhD, MScPhm, Eli Lilly Canada Inc, Scarborough, ON, Canada
PS1-51

ENGAGING PEOPLE LIVING WITH LUNG CANCER IN PROJECT TRANSFORM: INTEGRATING THE PATIENT EXPERIENCE INTO LUNG CANCER RESEARCH, TREATMENTS, AND POLICY
John Bridges, PhD, MEc1, Ellen Janssen, BA1, Andrea Ferris, MBA2 and Sydney Morss Dy, MD, MSc1, (1)Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, (2)LUNGevity, Chicago, IL
PS1-52

A METHODICAL STUDY OF AN ANALYTIC HIERARCHY PROCESS (AHP) CONCERNING THE DEVELOPMENT OF A CENTRAL INFORMATION PLATFORM FOR RARE DISEASES IN GERMANY
Frédéric Pauer, M. Sc., Institute of Risk and Insurance (IVBL), Center for Health Economics Hannover (CHERH), University of Hannover, Hannover, Germany
PS1-53

USING DELIBERATIVE METHODS TO GUIDE IMPLEMENTATION OF LUNG CANCER SCREENING
Daniel S. Reuland, MD, MPH1, Alison Brenner, PhD2, Laura Cubillos Braswell, MPH2, Maihan Vu, DrPH, MPH3, Louise Henderson, PhD4, Patricia Rivera, MD5, Katherine Birchard, MD6, Michael Pignone, MD, MPH1 and Russel Harris, MD MPH7, (1)University of North Carolina School of Medicine, Chapel Hill, NC, (2)Cecil G Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, (3)Center for Health Promotion and Disease Prevention. The University of North Carolina at Chapel Hill, Chapel Hill, NC, (4)Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, (5)Division of Pulmonary and Critical Care Medicine, University of North Carolina, Chapel Hill, NC, (6)Cardiothoracic Imaging Division, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, (7)Cecil G Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC
PS1-54

TRADING BANKRUPTCY FOR HEALTH IN THE UNITED STATES: A DISCRETE-CHOICE EXPERIMENT
Mark G. Shrime, MD, MPH1, Milton C. Weinstein, PhD2, Jessica Cohen, PhD2 and Joshua A. Salomon, PhD2, (1)Harvard University Interfaculty Initiative in Health Policy, Cambridge, MA, (2)Harvard School of Public Health, Boston, MA
PS1-55

USING EYE-TRACKING METHODS TO INVESTIGATE THE FRAMING OF RISK ATTRIBUTES IN DISCRETE CHOICE EXPERIMENTS
Caroline Vass, BSc, MSc1, Dan Rigby, BSc, MSc, PhD2, Stephen Campbell, BA, MA, PhD3, Kelly Tate, BSc4, Andrew Stewart, BSc, PhD4 and Katherine Payne, BPharm, MSc, PhD1, (1)Manchester Centre for Health Economics, The University of Manchester, Manchester, United Kingdom, (2)Department of Economics, The University of Manchester, Manchester, United Kingdom, (3)Centre for Primary Care, The University of Manchester, Manchester, United Kingdom, (4)School of Psychological Sciences, The University of Manchester, Manchester, United Kingdom
PS1-56

QUANTIFYING RANK ORDER DISCRIMIATION IN UNITS OF INFORMATION
William Benish, MS, MD, Case Western Reserve University, Shaker Heights, OH, Jarrod E. Dalton, PhD, Cleveland Clinic, Cleveland, OH and Neal V. Dawson, MD, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH
PS1-57

PROBABILISTIC SENSITIVITY ANALYSIS IN SEQUENTIAL DECISION MODELS
Qiushi Chen, BS, Georgia Institute of Technology, Atlanta, GA, Turgay Ayer, PhD, Georgia Insitute of Technology, Atlanta, GA and Jagpreet Chhatwal, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX
PS1-58

TIMED AUTOMATA MODELING OF THE PERSONALIZED TREATMENT DECISIONS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Stefano Schivo, PhD, Koen Degeling, BSc, Hendrik Koffijberg, PhD, Maarten J. IJzerman, PhD and Rom Langerak, PhD, University of Twente, Enschede, Netherlands
PS1-59

INCORPORATING PRIOR BELIEFS INTO CLINICAL DECISIONS
Robert Lew, PhD, Department of Veterans Affairs, Boston, MA, John Russo, PhD, computer science wentworth institute of technology, boston, MA, Chen-Hsiang Yu, PhD, Wentworth Institute of Technology, Boston, MA and Hongsheng Wu, PhD, Wentworth Institute of Technology, Boston, MA
PS1-60

ELICITING THE EFFECTS OF LIPID PROFILE ON QUALITY OF LIFE FOR TYPE 2 DIABETES PATIENTS
Niraj Kumar Pandey, M.S.1, Murat Kurt, PhD2 and Mark Karwan, PhD1, (1)University at Buffalo, The State University of New York, Buffalo, NY, (2)Merck Research Laboratories, North Wales, PA
See more of: 37th Annual Meeting of the Society for Medical Decision Making
<< Previous Session | Next Session >>